Filing Flows › Cartesian Therapeutics (RNAC) › Q1 2026 › vs Q1 2025
Cartesian Therapeutics (RNAC) Q1 2026 vs Q1 2025 (year over year)
Cartesian Therapeutics's revenue fell $1.0M (-93%) from $1.1M in Q1 2025 to $78K in Q1 2026.
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $78K | $1.1M | −$1.0M | -93% |
| Net loss | $39.2M | $17.7M | $21.5M | +121% |
| Costs & expenses | $39.3M | $23.0M | $16.3M | +71% |
| Operating costs | $26.6M | $23.0M | $3.6M | +16% |
| Interest & other, net | $12.7M | −$4.2M | $16.9M | — |
| Research & development | $19.5M | $14.7M | $4.8M | +33% |
| General & admin | $7.1M | $8.3M | −$1.2M | -14% |
| Operating cash sources | $39.2M | $17.7M | $21.5M | +121% |
| Depreciation | $600K | $600K | $0 | 0% |
| Share-based compensation | $2.4M | $2.5M | −$85K | -3% |
| Working capital & other | $14.0M | −$8.5M | $22.5M | — |
| Cash used in operations | $22.1M | $23.1M | −$973K | -4% |
| Net loss absorbed | $39.2M | $17.7M | $21.5M | +121% |
Questions
How much did Cartesian Therapeutics's revenue grow year over year in Q1 2026?
Cartesian Therapeutics's revenue fell $1.0M (-93%) from $1.1M in Q1 2025 to $78K in Q1 2026.